Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma

The immune checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab represent a substantial improvement in treating advanced melanoma but are associated with adverse events (AEs) likely related to general immunologic enhancement. To ensure that patients receive optimal benefit from these agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinstein, Alyona, Gordon, Ruth-Ann, Kasler, Mary Kate, Burke, Matthew, Ranjan, Smita, Hodgetts, Jackie, Reed, Vanessa, Shames, Yelena, Prempeh-Keteku, Nana, Lingard, Karla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995532/
https://www.ncbi.nlm.nih.gov/pubmed/29900017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995532/
https://www.ncbi.nlm.nih.gov/pubmed/29900017

Ejemplares similares